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Accurate target volume delineation is crucial for the radiotherapy of tumors. Diffusion and perfusion magnetic
resonance imaging (MRI) can provide functional information about brain tumors, and they are able to detect
tumor volume and physiological changes beyond the lesions shown on conventional MRI. This review examines
recent studies that utilized diffusion and perfusion MRI for tumor volume definition in radiotherapy of brain
tumors, and it presents the opportunities and challenges in the integration of multimodal functional MRI into
clinical practice. The results indicate that specialized and robust post-processing algorithms and tools are needed
for the precise alignment of targets on the images, and comprehensive validations with more clinical data are
important for the improvement of the correlation between histopathologic results and MRI parameter images.
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Background
Brain tumors
According to the World Health Organization (WHO)
classification, high-grade gliomas are the most malignant
primary intra-axial brain tumors in adults, and most
cases consist of glioblastoma multiforme (GBM, WHO
grade IV astrocytoma). Low-grade gliomas are much
less common, and most are WHO grade II gliomas [1].
Meningiomas are the most common primary extra-axial
brain tumors, and they account for approximately 20 % of
all brain tumors [2, 3]. Further, malignant and atypical
meningiomas are more prone to recurrence and aggres-
sive growth, increasing patient morbidity and mortality
[4]. Brain metastases are the second most common
intracranial tumors in adults (15–30 % of all intracra-
nial tumors) [5]. Most of them originate from lung cancer
(16–20 % incidence), melanoma (7 % incidence), renal cell
carcinoma (7–10 % incidence), and breast cancer (5 %* Correspondence: fengyu@ecu.edu
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(http://creativecommons.org/publicdomain/zeincidence) [6]. Therefore, we focus on these brain carcin-
omas in this review.Limitations of conventional magnetic resonance imaging
(MRI) in radiotherapy for brain tumors
Radiotherapy plays an important role in the treatment of
brain tumors [7]. To avoid missing the target and to
spare critical healthy brain tissue outside the target vol-
ume in radiotherapy, cancerous tissue involvement must
be correctly defined in the gross tumor volume (GTV)
delineation. Patients undergo a contrast-enhanced com-
puted tomography (CT) scan in the treatment position
as an initial step in radiotherapy planning for the delin-
eation of target volumes and organs at risk (OAR), as
well as treatment beam setup and dose calculation [7].
However, there are inherent limitations to CT in showing
satisfactory contrast in soft tissue, and it is insufficient
for obtaining comprehensive information about tumor
and the desired accuracy of the delineation. As a com-
plementary technique, conventional T1-weighted contrast-
enhanced and T2-weighted MRI reveal soft tissues with
higher contrast and could help improve the accuracy of
tumor volume definition [7, 8]. The significant practical
value of the integration of MR/CT data into treatment
planning in reducing target volumes and interobserverle is distributed under the terms of the Creative Commons Attribution 4.0
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based treatment planning using MRI simulation for
intracranial lesions has been developed and has shown
no significant differences compared with CT +MRI plans
in tumor control probability [12]. Recently, combined
positron emission tomography (PET)/MRI has become
available in clinical practice, offering the possibility of
imaging the anatomical and functional characteristics
of a tumor simultaneously, and it could improve radio-
therapy treatment planning and the evaluation of treat-
ment response [13, 14].
Although conventional MRI has been used in tumor
volume definition for nearly 20 years, it does not accur-
ately show the actual tumor borders of glial neoplasms
because tumor cells could be found in serial biopsies
beyond signal intensity changes on T2‑weighted MRI
images [15]. Because one of the major factors in treatment
failure of gliomas is the invasion of tumor cells into nor-
mal brain tissue, the definition of exact tumor borders has
been essential for safe and successful treatment adminis-
tration [16]. Currently, larger margins (e.g., a 2.0–2.5-cm
margin for WHO grade IV glioma) are added to the GTV
to generate the clinical target volume (CTV), which aims
to cover the microscopically pathologic volume around
the apparent tumor, including peritumoral edema and
infiltrating cells [1, 17, 18]. However, the irradiated vol-
ume defined with this method oftentimes involves normal
brain tissue, which is radiosensitive. It limits the total dose
that can be delivered to the target volume for killing
tumor cells, resulting in tumor recurrence within the
target volume [16, 19]. Furthermore, in the retreatment
of recurrent tumors, the risk of radiation necrosis and
the conservation of normal brain tissue should be con-
sidered for the delineation of accurate tumor extent.
Unfortunately, conventional MRI has shown significant
limitations, not only in tumor detection, target delinea-
tion and differentiation of the tumor from other disease
processes before radiotherapy but also in the discrimin-
ation of radiation treatment effects and recurrent tumors
after radiotherapy [20–22].
The potential value of advanced methods of diffusion and
perfusion MRI
The development of advanced imaging techniques, such
as diffusion and perfusion MRI, has enabled more sensi-
tive detection of the heterogeneity and invasion of tumors
than with conventional MRI. These novel methods pro-
vide functional information about tumor cellularity, prolif-
eration, disruption of white matter, tumor vascularity and
vessel permeability. All of these physiological changes
are involved in the tumor progression and invasion
processes, which could allow for improved tumor delin-
eation and assessment of tumor extent in radiotherapy
for brain tumor patients.Objectives
The purpose of this review is to examine recent studies
that have included the utilities of diffusion and perfusion
MRI for tumor volume definition during the course of
radiotherapy for brain tumors, including treatment plan-
ning and therapeutic response assessment. Both opportun-
ities and challenges for the integration of these advanced
functional imaging techniques into clinical practice are
presented.
Review
Diffusion MRI
Diffusion features and metrics
Diffusion-weighted imaging (DWI) measures random
water movement in tissue, and its derived parameter of
apparent diffusion coefficient (ADC) represents direction-
independent water displacement. In tissues with high
cellularity, free water motion is restricted, and the mea-
sured ADC is low, whereas in tissues with low cellular-
ity, the corresponding ADC is high [3]. This inverse
correlation between ADC and cellularity may serve as a
tool to differentiate more and less malignant glial tu-
mors. For meningiomas, the ADC map could be used
to differentiate the solid tumor from edema because the
ADC value in edematous areas is significantly higher
than that in solid tumor and normal brain tissue. More-
over, ADC has recently been shown to be correlated
with survival for brain metastases [23].
In diffusion tensor imaging (DTI), diffusion-weighted
images are acquired with six or more gradient direc-
tions, and three eigenvalues of the diffusion tensor are
calculated (λ1, λ2, λ3) to evaluate the water molecules’
movement on the X, Y and Z axes [24, 25]. Based on the
three eigenvalues, different tensor metrics, such as frac-
tional anisotropy (FA) and mean diffusivity index (MD),
can be calculated to quantify the amount of directional
water motion. The FA value ranges from 0 to 1, depend-
ing on the degree of directionally ordered brain tissues
in which water motion occurs, especially the brain fiber
alignment. For instance, 0 indicates that the water mole-
cules move in a completely homogeneous medium such
as cerebrospinal fluid (CSF), and one indicates water
movement in well-organized and highly directional struc-
tures, such as the axons and myelin sheathes of white
matter. Thus, the FA value is sensitive to the changes in
fiber bundles and might allow for better evaluation of the
disruption, displacement and infiltration of white matter
caused by tumor invasion in regions that appear normal
on conventional MR images. Furthermore, DTI fiber
tractography, which is calculated based on a specific
sub-voxel fiber tracking algorithm, can depict how the
presence of a brain tumor has disrupted the fiber integ-
rity [24, 26]. Because gliomas preferentially infiltrate
along white matter tracks, DTI could be used to predict
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planning [27].
Diffusion MR in treatment planning
The purpose of an MRI exam for radiotherapy treatment
planning is to utilize image information to create a precise
delineation of the target volume and to obtain an optimal
dose distribution [28]. Advanced imaging techniques might
be more promising for assessing the microenvironment
within a tumor, such as the cellular density, organization of
the cellular and extracellular space, margin of tumor inva-
sion, and white matter involvement in tumor infiltration,
compared with conventional anatomical MR images. Diffu-
sion metrics and fiber tractography derived from DWI/
DTI imaging techniques have been investigated to define
accurate tumor extent and delineate target volume in
radiation treatment planning and to guide surgery/
biopsy sampling [26, 29–38].
For high-grade gliomas, standard CT and MRI are
unable to demonstrate subclinical tumor spread, result-
ing in insufficient doses to peripheral regions of the
tumor to achieve good local tumor control. A new term
for such abnormalities, image-based high-risk volume
(IHV), which is distinct from GTV, was proposed by
Jena et al. for assessment of the value of DTI in the
individualization of radiotherapy treatment planning for
patients with high-grade gliomas [29]. In their study, the
non-uniform IHV was added to the GTV (defined on CT
or MRI) to include areas of abnormality on DTI, and the
CTV was generated by adding a 1-cm margin to the IHV.
Compared with the normal standard plan, the size of the
DTI-based planning target volume (PTV) was reduced by
approximately 18 to 46 % (mean 35 %), and it encom-
passed areas at high risk of tumor involvement and re-
sulted in escalated doses without an increase in normal
tissue complication probability (NTCP). In a recent re-
port, the isotropic component (p) and anisotropic compo-
nent (q) of the water diffusion tensor, calculated by DTI
data, were used to extend the CTV along the abnormal
tensor tracts to preserve coverage of the likely routes of
dissemination, while sparing uninvolved brain tissues [30].
Thus, although different areas within the standard CTV
have different probabilities of tumor infiltration, DTI
seems to show that a higher risk of infiltration occurs
around the tumor center, and it can be used as the basis
for the individualization of treatment volumes for high-
grade glioma patients [29].
Several novel methods have been investigated with
DTI metrics to improve the definition of tumor infiltration
margins in radiotherapy for malignant glioma patients. As
proved in a study of 17 patients with surgically treated
WHO grade IV gliomas, the ADC and FA values could be
used to identify ultra-structural changes in perilesional
hyperintensity areas (FA was significantly lower and ADCsignificantly higher than in the unaffected contralateral
tissue) and to help determine the tissue at risk of tumor
infiltration [32]. Price et al. showed that it was possible to
use the anisotropic component (q) and isotropic compo-
nent (p) of the water diffusion tensor to differentiate gross
tumor (decrease in q was more than 12 % than that in the
contralateral region) from tumor infiltration (increase of p
was more than 10 % than that in the contralateral region),
which could serve for better delineation of the tumor
margin for glioma treatment [33]. Moreover, a new
quantification method to solve problems in the reprodu-
cible determination of DTI-derived FA values was re-
ported and showed its feasibility for the reliable depiction
of white matter infiltration by gliomas [39]. Thus, when
the tumor is near critical, sensitive structures, and a stric-
ter boundary definition is required for radiation treatment,
DTI could serve as a promising tool to identify tissue at
risk of tumor infiltration and to spare uncancerous brain
tissue [32].
Based on the knowledge that glioma cells preferentially
spread along nerve fibers, there are new methods to
estimate the optimal radiation target volume to encom-
pass the whole tumor. The computational simulation
model for the pattern of glioma spread with white fiber
distribution information, based on DTI data, might be
one of the most promising approaches for estimating
tumor growth and determining the tumor margin for
radiotherapy, and it can help deliver a radio-surgical
boost to “high-risk” volumes in which the likelihood of
finding malignant cells is high [40]. Another method
for identifying the tumor invasion margin correctly was
proposed that uses a geodesic distance on the Riemannian
manifold of brain fibers to replace the Euclidean distance
used in clinical practice [31]. In this study, Cobzas et al.
used actual DTI data from patients with gliomas to com-
pute the geodesic distance, and they compared their
predicted tumor growth with follow-up MRI scans.
Compared to the conventional Euclidean distance, the
geodesic distance method could significantly improve
the prediction of glioma invasion margins, and these
computational simulation methods for the prediction of
the invasive margin of glioma showed potential for the
delineation of optimal radiation target volumes, although
further studies with more patient data are necessary to
validate their feasibility in clinical practice.
With DTI-derived fiber tractography, white matter
involvement by a tumor can be classified as displace-
ment, infiltration or disruption, compared with the nor-
mal unaffected tract on the contralateral side [36]. Fiber
tractography is critical not only for defining the effects of
invasive gliomas on white matter tracts but also for
demonstrating the relationships between white matter
structures and the cerebral neoplasm. Currently, this
technique has been employed in academic research to
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serve vital tracts while maximizing tumor resection or
local control [26, 35–37]. However, there currently are
several obstacles to integrating tractography into clin-
ical treatment planning systems. First, there is no “gold
standard” for accurately validating the reliability of
in vivo tractography [26]. Second, image-derived results
cannot yet determine the actual size of white matter
tracts [37]. With the continuous improvement of this
technology, however, fiber tractography still holds great
promise for the definition of cerebral tumor invasion
into white matter and for the improvement of radio-
therapy treatment.
Diffusion MR in the assessment of treatment response
For noninvasive tumors, such as meningiomas and me-
tastases, the conventional method to assess treatment
response is by changes in tumor volume on contrast-
enhanced T1-weighted MRI, while it is difficult to differ-
entiate therapy-related effects from tumor recurrence in
high-grade gliomas or anaplastic transformation in low
grade gliomas with conventional MRI [3]. With abnor-
mal hypercellularity and microvasculature, the invasive
growth of high-grade gliomas results in breakdown of
the blood-brain barrier (BBB), shown as a volume of
contrast enhancement on T1-weighted MRI images. The
edema and infiltration surrounding the tumor without
BBB disruption appear as hyperintensity on T2-weighted
MRI images but non-enhancement on T1-weighted MRI
images. Low-grade gliomas typically exhibit no contrast
enhancement, but they become contrast enhancing when
there is anaplastic transformation to high grade. However,
the appearance becomes complex after therapy because
the treatment-induced effects, such as necrosis, also lead
to BBB breakdown, similar to tumor progression and
recurrence. Recent studies have investigated advanced
imaging methods, such as DWI and DTI, for the reli-
able identification of these entities and the adjustment
of radiotherapy planning as early as possible.
A study of DTI-derived ADC values in new contrast-
enhancing lesions and perilesional edema in 28 patients
previously treated for brain tumors (GBMs, oligodendrogli-
omas and astrocytomas of grades II and III) was reported,
and these values showed their capacity to distinguish re-
current neoplasms from treatment-related injuries [41].
Although a high cell-density tumor and radiation-induced
injury both restrict water mobility and lead to a lower
ADC, the increased extracellular space and micronecrosis
in areas of tumor recurrence can eventually cause higher
ADC values [41]. Thus, ADC values in contrast-enhancing
lesions and ADC ratios (ADC in the pathological area
divided by ADC in the mirror contralateral area) in the
white-matter tracts in perilesional edema were signifi-
cantly higher for the recurrence group than for thenon-recurrence group (P = 0.01). Additionally, FA values in
contrast-enhanced lesions after radiotherapy for patients
with astrocytomas may also be used to differentiate radi-
ation necrosis from tumor recurrence [41, 42]. Although
astrocytomas tend to destroy the integration of white
matter fibers and cell structures, resulting in decreased
FA values, histological characteristics such as cellularity
and vascularity also influence FA values, finally causing
tumors of higher grade to show higher FA values in
contrast-enhanced areas. In contrast, radiation necrotic
tissue with no normal fibers accounts for the lower FA
value in the enhanced lesion than that of the recurrent
tumor [42], making it possible to differentiate radiation
necrosis from tumor recurrence using FA values.
For the early prediction of response to the treatment
of gliomas, Lemasson et al. evaluated a voxel-based image
biomarker, the functional diffusion map (fDM), to detect
the heterogeneity of tumor response in a radiation dose
escalation protocol [43]. By first calculating the difference
between the ADCs before and after therapy, fDM was
determined within the total tumor and was classified into
three categories – fDM+, fDM− and fDM0 – indicating
increased, decreased, and unchanged ADC, respect-
ively. The study showed that treatment induced a dose-
dependent increase in ADC values of tumors, and fDM+
was able to improve the detection of dose-dependent
trends in tumor response. Thus, fDM could be used in the
future for adaptive conformal targeting of specific tumor
regions exhibiting resistance [43].
In the assessment of radiation-induced white matter
injury, DTI is regarded as the most sensitive technique
for the identification of white matter abnormalities before
anatomical changes on conventional MRI images. A re-
cent analysis showed that ADC values based on DTI could
serve as a biomarker for the determination of long-term
radiation-related injury to white matter [44]. The results
demonstrated that the structural integrity of white matter
underwent changes after radiation therapy starting as early
as when the received total dose reached 5 to 15 Gy. Fur-
thermore, a mean ADC increase of 8 %, compared to nor-
mal white-matter tissue, was detectable at total radiation
dose levels of 15 to 45 Gy because of diffuse post-
irradiation white matter injury, such as reactive astrocy-
tosis, edema or demyelination. Thus, this technique has
shown great promise in radiation-induced white-matter
injury assessment, but rigorous clinical validation is also
required to evaluate its potential in treatment response
assessment.
For the management of GBM patients with recurrence
after primary radiotherapy, re-irradiation is one of the
salvage treatment options. However, treatment-related
morbidity becomes a major concern due to the reduced
radiation tolerance of normal tissue after initial treatment
[45]. Thus, the improvement of techniques for target
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role in safe radiation administration with fewer adverse
effects. The retreatment target volume should therefore
be minimized to decrease the probability of normal
brain necrosis and to improve the overall survival of
recurrent GBM patients [46, 47]. Using the tissue signa-
ture method, Price et al. defined a region around a
tumor with a reduced anisotropic component (q) due
to tumor disruption and an area outside the increased
isotropic component (p) due to tumor infiltration [48].
This technique could lead to smaller treatment volumes
by tailoring the high-dose region to high-risk areas for
subclinical spread [49]. Furthermore, it has been shown
that 95 % of tumor progression occurs within 2–3 cm
of the resection cavity, and the vast majority of patients
(>80 %) continue to recur within 2 cm of the re-irradiated
volume [45, 50]. Thus, Krishnan et al. determined the
direct and unique clinical utility of DTI tractography in
treatment planning, in which target volumes were modi-
fied to provide elongated treatment margins along the
paths of elevated water diffusion, creating biologically
better treatment that may reduce the incidence of pro-
gression [50]. Therefore, DTI has high inherent ability
to improve radiotherapy target delineation by creating a
biologically better treatment plan that may reduce the
incidence of progression [51].
The utilization of DWI/DTI metrics is summarized in
Table 1. These studies revealed that diffusion MRI is critical
for making decisions about tumor delineation with more
accurate margins in treatment planning. The factors that
influence these DTI metrics include edema, tumor necrosis,
the density of tumor cells, and treatment effects. Thus, fur-
ther validations with detailed histologic sampling improved
the placement of regions of interest (ROIs), and reduced
errors in multimodal image registration are necessary for
the application of these parameters to obtain valuable infor-
mation for tumor volume definition in radiotherapy.Table 1 The utilization of DWI/DTI-derived metrics in brain tumor tr
Utilities DWI DTI
ADC MD FA
Tumor cellularity [75] [38] [38]
Prognosis
Invasion [31, 32,
RT treatment planning [29, 30]
Surgery guidance [38] [36–38]
Response to treatment [43]
Treatment effect
Distinguishing tumor recurrence from treatment effect [41, 42]
Re-irradiation treatment planning
DWI diffusion weighted imaging, DTI diffusion tensor imaging, ADC apparent diffusPerfusion MRI
Perfusion MRI and vascular properties
Malignant gliomas are able to recruit and synthesize
vascular networks for growth, proliferation and metas-
tasis. Because of rapid tumor cell growth, the vascula-
ture of malignant gliomas may consist of a high density
of immature and leaky blood vessels in the periphery of
the tumor and regression and low density of vessels in
the core of the tumor [19]. Without new blood vessels
that form to supply oxygen and nutrients to cells, the
diameter of the solid tumor volume can only reach 2 mm.
Thus, vascularity is crucial to the categorization of the
malignant potential of intra-axial tumors, with direct con-
sequences for therapeutic management [3], whereas in
benign neoplasms such as meningioma, vascular prolifera-
tion occurs by recruiting existing capillaries and not
angiogenesis so that biopsies of high vascularity are not
observed in these tumors [16, 52]. Several advanced MRI
techniques have been investigated to assess the vascula-
ture of brain tumors with perfusion evaluation, including
dynamic-susceptibility contrast (DSC), dynamic-contrast
enhanced (DCE) and arterial spin-labeling (ASL) tech-
niques. For DSC and DCE MRI, intravenous injection of a
bolus of gadolinium-diethylenetriaminepentaacetic acid
(Gd-DTPA) is necessary to assess parameters such as
cerebral blood volume (CBV), cerebral blood flow (CBF)
and transfer constant (Ktrans).
DSC imaging uses a series of T2*‑weighted echo planar
MR sequences to assess the first-pass of a contrast bolus
in brain tissue in which signal loss occurs because of the
increase in contrast agent concentration. According to
the indicator dilution theory for intravascular tracers,
voxel-based CBV maps can be created by integrating
the area under the concentration-time curve of the
contrast agent. With the measurement of arterial input
function (AIF) and pharmacokinetic models, the CBF
map can be estimated voxel by voxel. Another commoneatment course
ADC Eigenvalues Tractography Isotropic (p) and anisotropic (q)
components
[34]
39] [32] [33]
[30, 33]
[36] [26, 35]
[44]
[41] [41]
[50] [48]
ion coefficient, MD mean diffusivity, FA fractional anisotropy, RT radiotherapy
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mean transit time (MTT), which can be easily calculated
according to the central volume theorem as follows [53]:
CBF ¼ CBV
MTT
: ð1Þ
In clinical practice, these quantities are often not
calculated for absolute but for relative measurement,
and they are called relative CBV (rCBV), relative CBF
(rCBF) and relative MTT (rMTT). Additionally, several
time-related parameter maps, such as the percentage of
base at peak (PBP) and time to peak (TTP), are measured
for the detection of abnormal signals in the brain tumor
tissue. The overall tumor vascularity can be depicted by
these parameter maps derived from perfusion MRI, such
as rCBV, rCBF and rMTT (Fig. 1), and the local varia-
tions in regional parameters could reflect the tumor
vascularity alterations, which are correlated with tumor
angiogenesis [54].
DCE imaging uses T1‑weighted sequences to identify
the changes in the MR signal when the bolus of contrastFig. 1 Images of a patient with an untreated glioblastoma multiforme (GBM
volume (rCBV) map; c relative cerebral blood flow (rCBF) map; d relative magent passes through the blood vessels and leaks into
the interstitial space as the BBB is disrupted. Therefore,
dynamically generated images can reveal regional micro-
vascular properties, such as vascular permeability (which
can be depicted by Ktrans) and the extravascular extracellu-
lar space (Ve) in and around the tumor. The estimation of
parameters derived from the dynamic data includes Ktrans,
fractional blood volume (fBV), and flux rate constant
(Kep), which have been found to be correlated with tumor
grade, microvascular density (MVD), tumor recurrence
and survival outcome [3, 24].
In contrast to DSC and DCE, ASL employs water mole-
cules in tissue as a freely diffusible intrinsic tracer to
measure CBF in tumor tissue. Upstream of the imaging
section, reversed phase or saturated radiofrequency pulse
sequences mark the hydrogen protons in arterial blood.
When the magnetically labeled protons transfer from the
labeling section into the imaging region through the
bloodstream, they interact with the non-labeled tissue
water in the capillaries. Thus, the static magnetization
vector in tissue decreases because of blood flow and T1). a T1-weighted contrast-enhanced image; b relative cerebral blood
ean transit time (rMTT) map
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sity. Subsequently, rCBF maps are calculated by the
comparison of the T1 relaxation time between images
acquired with and without magnetically labeling. As a
totally noninvasive and quantitative technique, ASL has
shown promise in prognosis and treatment response
evaluation for brain tumors.
Perfusion MRI in tumor volume definition
Accurate margin definition for gliomas has been a chal-
lenge in radiotherapy. The tumor perfusion parameter
maps derived from DSC and DCE imaging, including
rCBV, rMTT and Ktrans, provide information about tumor
vascularity that is reflective of tumor invasion and allows
for improved tumor volume delineation [55–58], as well
as determination of aggressive or infiltrating tumor sub-
volume in radiotherapy treatment planning [59, 60].
The significant tissue heterogeneity in gliomas, consisting
of varying amounts of cellular and nuclear pleomorphism,
mitotic activity, microvascular proliferation and necro-
sis, leads to the signal diversity in perfusion imaging
data [54]. Thus, isolated perfusion parameter is insuffi-
cient, and multiparametric methods should be devel-
oped for complementary depiction of the whole tumor,
which could result in better definition of tumor mar-
gins. Durst et al. applied a multimodal imaging scheme
with rCBV, rCBF, rMTT, Ktrans, MD and FA to predict
the extent of glioma invasion with a significant correl-
ation with histopathology [59]. In their study, advanced
multimodal neuroimaging sequences and stereotactic
biopsy coordinates were co-registered, and the perfu-
sion and diffusion parameters were assigned to the bi-
opsy sites. Multivariate analysis was used to build the
final model describing nuclear density, and it showed
apparent correlation between the predicted and observed
nuclear density. Therefore, with the multiparametric
scheme, the radiation oncologist could shape the radiation
field more accurately, treat the sites most likely to recur
while sparing healthy tissue, and ultimately improve pa-
tient outcomes [59].
There are different components in a glial neoplasm,
including cancerous tissue, pure edema, cellular prolifera-
tion, vascular proliferation, cellular infiltration and necro-
sis, and the number of components increases with the
tumor grade. To differentiate different biological tumor
components and to determine tumor borders between
peritumoral edema and infiltration areas, rCBV values
in different morphological areas (e.g., solid appearing,
edematous appearing) were evaluated [55]. In the peri-
enhancing areas with abnormal signals on conventional
contrast-enhanced MR images for gliomas, rCBV proved
significantly higher in cancerous tissue, lower in normal
tissue, and intermediate in the infiltrating tumor, perhaps
providing useful information for improving the definitionof glioma extent and grade [56]. For malignant gliomas
such as GBMs that exhibit extensive infiltration in the
surrounding tissue along the white matter tracts and
perivascular spaces, rCBV shows statistically significant
differences in different apparently edematous areas sur-
rounding the enhanced margins of GBMs. The results
of calculating the ratio of rCBV in the tumor to rCBV
in the contralateral normal white matter in Di Costanzo’s
report showed a higher rCBV ratio (mean value = 1.42) in
the infiltrating tumor, a lower rCBV ratio (mean value =
0.36) in pure edema, and an intermediate rCBV ratio
(mean value = 0.97) in tumor-infiltrated edema [57]. The
findings in this study could have significant implications
for improving the evaluation of GBM extent in radiation
treatment planning. For further practice, clinical trials to
correlate multimodal MR data with histopathological
findings are needed. Furthermore, rather than deter-
mining the tissue to be either healthy or tumorous, consid-
ering it as a continuum from healthy tissue to poorly
differentiated tumor tissue might be more meaningful [61].
Perfusion MRI in therapeutic response assessment
In the assessment of tumor response to treatment, i.e.,
distinguishing tumor recurrence or progression from
treatment effects in brain tumors, the measurements of
rCBV, rCBF and Ktrans in DSC, DCE and ASL have shown
advantages beyond conventional MRI.
For high-grade gliomas, especially GBM, monitoring
the treatment response to radiotherapy remains difficult
because the frequent occurrence of early changes on
contrast-enhanced MR images, such as radiation necrosis,
can mimic tumor progression, which is called pseudo-
progression. Although the precise mechanism of post-
radiotherapy pseudo-progression remains unknown, there
is a hypothesis that radiation-induced vascular changes
may lead to a focal transient increase in gadolinium en-
hancement [62, 63]. In addition, the tumor-mimicking
lesions of pseudo-progression lack angiogenesis and are
stabilized without changes during treatment, different
from real tumor progression [3]. Thus, the vascular
property measurements, such as cerebral blood volume
and vascular permeability, are promising for distinguishing
true progression from pseudo-progression. An innovative
method called parametric response mapping (PRM) was
applied to quantify early hemodynamic alterations after
treatment by calculating the differences between serial
rCBV maps (ΔrCBV = rCBVintratreatment – rCBVpretreatment)
for each voxel within the GTV [63]. Furthermore, a sig-
nificantly reduced blood volume (PRMrCBV) at week 3
in the progressive disease group compared with the
pseudo-progression group (P < 0.01) shows the potential
ability of rCBV in distinguishing pseudo-progression from
true progression in patients with high-grade glioma. An-
other new imaging biomarker of tumor progression based
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tumor burden (pMRI-FTB), was also proposed, and it
determines the percentage of tumor voxels relative to
total lesion mask voxels using the optimized rCBV
threshold. Moreover, pMRI-FTB is significantly corre-
lated with the histologic tumor fraction (P < 0.0001)
and overall survival (P < 0.02) [64]. Moreover, in a recent
report, relative Ktrans (rKtrans), initial area under the con-
centration curve (riAUC) and rCBV value in the recurrent
group proved to be significantly higher than the values in
the group with treatment-induced changes, and DCE
showed no significant differences from DSC in differenti-
ating power [65]. These methods hold great potential for
treatment response assessment and could find greater
application in clinical practice with more precise and
detailed investigation in a larger glioma population.
In addition to gliomas, rCBV measurement in tumor
and normal tissue after radiotherapy has been used to
evaluate the response of extra-axial brain tumors such as
meningiomas. Because the location of a neoplasm is near
the skull base and orbit, susceptibility artifacts can lead
to image distortion in perfusion-weighted echo planer
imaging sequences (EPI) such as DSC. To resolve this
problem, a recent study performed pseudo-continuous
arterial spin labeling (pcASL) methods and showed that
the maximum tumor blood flow (mTBF, the maximum
rCBV value in ROIs placed in tumor tissue showing en-
hancement) was correlated significantly with the changes
in tumor volume before and after radiotherapy [66].
According to the results, mTBF could serve as a poten-
tial biomarker of tumor volume for assessing thera-
peutic response without contrast agents, and future
investigations should also be conducted by comparing
the advantages of pcASL to those of other perfusion
imaging techniques such as DSC and DCE.
For prognosis, the alterations of rCBF in ASL and
DSC imaging at the 6-week follow-up after stereotactic
radiosurgery for brain metastases were highly predictive
of treatment outcome [5]. A recent study investigating
radiation response for brain metastases also reported that
responders showed a significant lower square of Ktrans
(Ktrans
2) and reduced rCBF at the 1 week follow-up, and
progressive lesions showed significantly lower rCBF and
reduced rCBV at the 1-month follow-up [67]. Considering
that the differences in radiation dose among different
patients can cause changes in vascular perfusion and
permeability, clinical trials investigating the impact of
biologically effective doses on parameter maps are needed
for the further validation of perfusion imaging techniques
for prognosis.
In the re-irradiation treatment planning of recurrent
high-grade gliomas, perfusion MRI is mainly performed
for the purpose of differentiating recurrent tumors
from radiation changes, along with pseudo-progressionas mentioned above. In addition, several investigations have
begun to incorporate perfusion MRI into re-irradiation
treatment plans for tumor border identification of re-
current brain tumors. For instance, Kim overlaid rCBV
and radiation dose maps on conventional MR to delin-
eate differences in identified tumor burdens for patients
with recurrent high-grade glioma [68]. According to
the results, rCBV maps of one-half of the patients
showed tumors outside the planning volumes, while the
remainder showed that the treatment volumes were over-
laid with uninvolved brain tissues. Thus, rCBV maps
proved to be helpful in determining unique regions of po-
tential tumor burden in recurrent high-grade glioma com-
pared to conventional MRI. Moreover, semi-quantitative
histogram analysis of the normalized CBV for contrast-
enhanced lesions showed potential in the prediction of
the volume fraction of post-treatment high-grade gli-
oma recurrence, which could help in the determination
of tumor extent [69]. Additionally, the stripe-like pattern
of increased rCBV adjacent to the contrast enhancement
on T1-weighted MRI of GBM at follow-up might indicate
infiltration transforming into future tumor recurrence
[70]. The treatment volume could be modified according
to the area with increased rCBV to target the high-risk
biological marginal recurrence and to reduce exposure of
viable brain tissue to high radiation doses.
The utilities of PWI metrics are summarized in Table 2.
To define accurate tumor-invasive borders for radiation
treatment, rCBV derived from DSC seems to be the most
common and promising parameter because it shows sig-
nificant differences among peritumoral edema, infiltration
areas and normal tissue. To become a tool in clinical rou-
tine, it would be desirable to conduct further investigations
with larger study populations and detailed histopathologic
findings and to strengthen the validity of these parameters
as imaging markers to define the exact location of the
border between tumor and healthy tissue.
Integration of multimodality imaging data
Isolated diffusion/perfusion parameters only reveal par-
tial information about brain-tumor microenvironments
and are insufficient to enable clinicians make crucial
decisions throughout the whole treatment. Properties
associated with the presence of a tumor might not be
correlated with each other perfectly (Fig. 2), and char-
acteristics examined by different imaging techniques do
not co-localize well in all patients [61]. For instance,
ADC essentially reflects the density of cells and the
extra-cellular extra-vascular space, whereas Ktrans re-
flects the micro-vessel density and permeability of the
vasculature [61]. Thus, the combination of advanced
MR imaging techniques such as DWI/DTI, DSC and
DCE is able to assess tumor cellularity, infiltration, and
vascularity properties simultaneously. The integration
Table 2 The utilization of PWI-derived metrics in brain tumor treatment course
Utilities DSC DCE ASL
rCBV rCBF rMTT Ktrans Ktrans/rKtrans riAUC rCBF
Prognosis [67] [5] [67] [5]
Invasion [58] [59] [59]
RT treatment planning [55–57]
Response to treatment [63] [66]
Progression vs. pseudo-progression [63]
Distinguishing tumor recurrence from treatment effect [64, 65] [65] [65]
Re-irradiation treatment planning [68–70]
DSC dynamic susceptibility-weighted contrast-enhanced perfusion MRI, DCE dynamic contrast-enhanced MRI, ASL arterial spin-labeling, rCBV relative cerebral
blood volume, rCBF relative cerebral blood flow, rMTT relative mean transit time, Ktrans transfer constant, rKtrans relative Ktrans, riAUC initial area under the
concentration curve
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gated with increasing interest in recent studies and has
shown promise in tumor differentiation, grading, accur-
ate tumor extent definition and therapeutic response
determination. For example, the integration of parameterFig. 2 Multimodal images of a patient with glioblastoma multiforme (GBM
c apparent diffusion coefficient (ADC) map, d fractional anisotropy (FA) m
blood flow (rCBF) map. In the heterogeneous enhancement region (indicated
different from each othermaps such as ADC, FA and rCBV derived from diffu-
sion and perfusion MRI data have been used to differ-
entiate among GBMs, solitary brain metastases, and
primary cerebral lymphomas [71] to serve as indicators
of glioma proliferation [72], to predict tumor infiltration). a T1-weighted contrast-enhanced image, b T2-weighted image,
ap, e relative cerebral blood volume (rCBV) map, f relative cerebral
by arrows), these properties on anatomical and functional images are
Guo et al. Radiation Oncology  (2016) 11:123 Page 10 of 13in patients with gliomas [59], to evaluate glioma grading
and to segment tumor, edema, necrosis, CSF and normal
tissues [73].
Additionally, an imaging technique for the evaluation
of tissue metabolism in tumors, called proton magnetic
resonance spectroscopic imaging (1H-MRSI), has also
been integrated into the multiparametric MRI assess-
ment of the accurate extent of brain tumors. By evalu-
ating the spatial distribution of substances correlated
with metabolic activity in tumor tissue, including choline
(Cho), N-acetylaspartate (NAA), creatine (Cr), lipids and/
or lactate (LL), 1H-MRSI was used to differentiate differ-
ent biological tumor components and to determine tumor
borders for radiotherapy planning [74]. In a recent report,
Grams et al. established and evaluated a multimodal
imaging concept that included Cho/Cr ratio, NAA-
concentration and rCBV derived from 1H-MRSI and
DSC [55]. With this method, different groups of tumors
with different multimodal imaging characteristics such
as “true edema,” “cellular infiltration,” “cellular prolifer-
ation” and “tumor” were identified for patients with gli-
omas. Furthermore, the combination of normalized Cho,
NAA, Cr and LL obtained by 1H-MRSI, ADC obtained by
DWI and rCBV obtained by PWI was used to improve the
delineation of GBMs [57], and the significant differences
in multi-parameters (Cho, NAA, Cr, LL, ADC, and rCBV)
in tumor mass and perienhancing areas could help in
distinguishing among different tissues, not only among
infiltrating tumor, vasogenic edema and normal tissue
but also between high- and low-grade gliomas [56]. In
another report, with the multimodal imaging data of
DWI, PWI, and 1H-MRSI, the authors showed that a
more optimal and safe planning target volume could be
obtained [57].
For routine clinical application, opportunities and chal-
lenges exist side by side for the integration of multimodal
MRI data into radiotherapy treatment planning. Because
the multimodal imaging course takes a long time, which
can induce motion artifacts by patients, and because of
the instinct for registration errors to exist in the post-
processing course due to the differences among imaging
mechanisms, the accuracy of the definition of tumor
borders might be affected. When strict tumor volume
delineation is required due to the existence of some
critical and sensitive anatomic structures around the
tumor, the reduction of mismatches among multimodal
images should be the most urgent issue to be resolved
in MR multi-parameter analysis. Additionally, there are
registration errors between localized ROI placement on
MR images and the stereotactic biopsy locations, which
can lead to uncertainty in the validation of those multi-
modality methods. To compensate for these registration
errors, Hu et al. [64] used small craniotomy sizes
and visually validated stereotactic image locations withintracranial neuroanatomical landmarks to minimize brain
shift, leading to misregistration no greater than 1–2 mm.
Future perspectives
These prospective studies mentioned above have proved
that diffusion and perfusion MRI techniques and the
quantitative metrics derived from these data are valuable
for providing additional information about brain tumor
pathophysiology. Patients with varied brain tumors can
benefit considerably from the combination of diffusion
and hemodynamic data with conventional MR exami-
nations for tumor volume and invasive extent definition,
as well as tumor response to treatment assessment in
radiotherapy.
For the clinical implementation of diffusion and perfu-
sion MRI data in radiotherapy, more effort are needed
(1) to improve the imaging technology to shorten the
MRI data acquisition time and reduce the motion arti-
facts of patients while retaining a relatively high image
quality at the same time; (2) to investigate specialized
and robust image registration algorithms for conven-
tional and functional advanced MRI images to minimize
mismatch errors in multimodal images post-processing;
(3) to apply sufficient clinical experiments and data evalu-
ations for comprehensive understanding and improve-
ment of the correlation between detail histopathology
results and functional information on MR parameter
images and to prove the significance of functional MRI
parameters; and (4) to determine the targets that should
receive higher radiation doses based on the physiological
information of functional MRI parameters correlated with
tumor proliferation and aggressiveness.
Additionally, automatic tools or software integrated into
a uniform radiotherapy treatment planning system (TPS)
for rapid and reliable trimodal or multimodal image fusion
of all of the functional imaging data are not yet available.
The dual-modality image fusion techniques provided in
current TPS can fuse and display two image sets in one
panel and one operation, which is inconvenient for target
definition in situations in which three or more sets of
complementary information from conventional and func-
tional MRI images are needed and used simultaneously.
Thus, the development of new robust image fusion tech-
niques that can fuse and display all image sets in one
panel and one operation will be a major task in the
coming years, and achieving this goal will also be help-
ful for conducting long-term prospective studies for the
evaluation of the effectiveness of multimodal functional
MRI techniques regarding the survival of patients with
brain tumors.
Conclusion
The combination of diffusion and hemodynamic data with
conventional MR examinations for treatment planning
Guo et al. Radiation Oncology  (2016) 11:123 Page 11 of 13and response assessment in radiotherapy will consider-
ably benefit brain-tumor patients. Opportunities and
challenges exist side by side for integration, and suffi-
cient clinical experiments and data evaluations are
needed. The development of new robust tools that can
fuse and display all image sets into one panel and in
one operation will be a major task in coming years,
which could be helpful for conducting prospective
studies for the evaluation of effectiveness.
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